Amgen Stock Quote Today

AMGN
 Stock
  

USD 252.09  3.73  1.50%   

Market Performance
4 of 100
Odds Of Distress
Less than 39
Amgen is selling for 252.09 as of the 10th of August 2022. This is a 1.50% increase since the beginning of the trading day. The stock's open price was 248.36. Amgen has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Amgen Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2021 and ending today, the 10th of August 2022. Click here to learn more.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 563.27 M outstanding shares of which 17.33 M shares are presently shorted by private and institutional investors with about 4.89 trading days to cover. More on Amgen Inc
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Amgen Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Amgen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Amgen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Over 82.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.gurufocus.com: Top 5 2nd Quarter Trades of Hikari Tsushin, Inc. - GuruFocus.com
ChairmanRobert Bradway
SEC FilingsAmgen Security & Exchange Commission EDGAR Reports
Thematic Ideas
Showing 3 out of 6 themes
Fama & French Classification
Average Analyst Recommendation
Analysts covering Amgen report their recommendations after researching Amgen's financial statements, talking to executives and customers, or listening in on Amgen's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Amgen Inc. The Amgen consensus assessment is calculated by taking the average forecast from all of the analysts covering Amgen.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Amgen Inc based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Amgen Inc financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares600.5 M570 M
Notably Up
Decreasing
Slightly volatile
Weighted Average Shares Diluted605 M573 M
Notably Up
Decreasing
Slightly volatile
Net Cash Flow from Operations10 B9.3 B
Significantly Up
Increasing
Slightly volatile
Total Assets70 B61.2 B
Fairly Up
Increasing
Slightly volatile
Total Liabilities55.5 B54.5 B
Fairly Up
Increasing
Slightly volatile
Current Assets23.7 B19.4 B
Fairly Up
Decreasing
Stable
Current Liabilities12.1 B12.2 B
Slightly Down
Increasing
Slightly volatile
Total Debt35.5 B33.3 B
Notably Up
Increasing
Slightly volatile
Return on Average Assets0.10.095
Notably Up
Increasing
Slightly volatile
Gross Margin0.730.752
Sufficiently Down
Decreasing
Slightly volatile
Asset Turnover0.410.418
Fairly Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Amgen's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyFairly Valued
Financial Strength
Amgen's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Amgen's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Amgen's bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Amgen's outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amgen's financial leverage. It provides some insight into what part of Amgen's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Amgen's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Amgen deploys its capital and how much of that capital is borrowed.
Liquidity
Amgen cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 36.85 B in liabilities. Amgen Inc has a current ratio of 1.41, which is within standard range for the sector. Debt can assist Amgen until it has trouble settling it off, either with new capital or with free cash flow. So, Amgen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amgen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amgen to invest in growth at high rates of return. When we think about Amgen's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

10.02 Billion
Amgen Inc (AMGN) is traded on NASDAQ Exchange in USA. It is located in One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States and employs 24,200 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with current market capitalization of 138.7 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amgen's market, we take the total number of its shares issued and multiply it by Amgen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Amgen Inc conducts business under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 563.27 M outstanding shares of which 17.33 M shares are presently shorted by private and institutional investors with about 4.89 trading days to cover. Amgen Inc currently holds about 6.54 B in cash with 9.32 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.25.
Check Amgen Probability Of Bankruptcy
Ownership
Amgen Inc retains a total of 563.27 Million outstanding shares. The majority of Amgen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amgen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amgen. Please pay attention to any change in the institutional holdings of Amgen Inc as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Amgen Ownership Details

Amgen Stock Price Odds Analysis

What are Amgen's target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Amgen jumping above the current price in 90 days from now is about 9.16%. The Amgen Inc probability density function shows the probability of Amgen stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Amgen has a beta of 0.3161. This suggests as returns on the market go up, Amgen average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Amgen Inc will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0983, implying that it can generate a 0.0983 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 252.09HorizonTargetOdds Above 252.09
90.63%90 days
 252.09 
9.16%
Based on a normal probability distribution, the odds of Amgen to move above the current price in 90 days from now is about 9.16 (This Amgen Inc probability density function shows the probability of Amgen Stock to fall within a particular range of prices over 90 days) .

Amgen Historical Income Statement

Amgen Inc Income Statement is one of the three primary financial statements used for reporting Amgen's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Amgen Inc revenue and expense. Amgen Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Amgen Net Income Common Stock is quite stable at the moment as compared to the past year. The company's current value of Net Income Common Stock is estimated at 6.49 Billion. Operating Income is expected to rise to about 8.6 B this year, although the value of Direct Expenses will most likely fall to about 5.1 B. View More Fundamentals

Amgen Stock Against Markets

Picking the right benchmark for Amgen stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Amgen stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Amgen is critical whether you are bullish or bearish towards Amgen Inc at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Amgen without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Premium Stories Now

   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module

Amgen Corporate Directors

Amgen corporate directors refer to members of an Amgen board of directors. The board of directors generally takes responsibility for the Amgen's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Amgen's board members must vote for the resolution. The Amgen board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Frank Herringer - Independent DirectorProfile
Francois Carbonnel - Independent DirectorProfile
Rebecca Henderson - Independent DirectorProfile
Sanders Williams - Independent DirectorProfile

Invested in Amgen Inc?

You need to understand the risk of investing before taking a position in Amgen. The danger of trading Amgen Inc is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amgen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amgen. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amgen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Amgen Stock analysis

When running Amgen Inc price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine Amgen value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.